1. VTE in Cancer

2. Risk of Cancer-Associated VTE

3. Risk Factors for Cancer-Associated VTE Cancer Site

4. Risk Factors for Cancer-Associated VTE Cancer Treatment Modality

5. Risk Factors for Cancer-Associated VTE Patient-Related Factors

6. Guideline Recommendations Cancer-Associated VTE Treatment

7. Challenges With LMWH

8. Persistence With Anticoagulation for Cancer-Associated VTE

9. VTE and Major Bleeding Risk in Patients Receiving Chemotherapy: A Real-World Analysis

10. Treatment of Cancer-Associated VTE Clinical Trials of NOACs

11. Hokusai VTE-Cancer Design

12. Hokusai VTE-Cancer Primary Outcome

13. Hokusai VTE-Cancer Primary Outcome Components

14. SELECT-D Design

15. SELECT-D Primary Endpoint – Recurrent VTE at 6 Months

16. SELECT-D Major and CRNM Bleeding at 6 Months

17. SELECT-D Major Bleeding by Tumor Type

18. Hokusai VTE-Cancer Major Bleeding by Tumor Type

19. NOACs for Treatment of Cancer-Associated VTE: Guidance From ISTH

20. Anticoagulation in Cancer Patients With Thrombocytopenia: Guidance From ISTH

21. Guidance for Prevention of Cancer-Associated VTE

22. CASSINI Design

23. AVERT Design

24. Summary

25. Summary (cont)

26. Abbreviations

27. Abbreviations (cont)